早发型精神分裂症相关circRNA-miRNA多分子调控网络的临床评估与验证研究

多分子调控网络指导精神分裂症的临床诊疗工作，是目前精神分裂症“精准医疗”的国际研究前沿。本研究选取处于神经发育敏感期的早发型精神分裂症患者为研究对象，采用病例对照和前瞻性追踪研究的实验设计，整合基因调控表达的多层面指标，利用生物信息学方法构建以血浆cirRNA和miRNA相互作用为核心的早发型精神分裂症的复合基因调控网络，并进行临床验证和诊断评价，以期来寻找用于早发型精神分裂症诊断的多分子网络标记。对此问题的阐明，将为精神分裂症生物标记物的研究提供新的思路，丰富精神分裂症“精准诊疗”的内容，同时也为提高该病目前的诊疗水平提供更具针对性的策略。

Multiple molecular regulation network serving as the biomarker for schizophenria diagnosis and treatment is the international research front of “Precision Medicine” of schizophrenia. This study will select early-onset schizophrenia (EOS) in neural development critical period as test subjects, adopt case-control and prospective study design, integrate multiple level indicators on gene expression regulation, utilize bioinformatics methods, and finally construct the plasma cirRNA-miRNA interaction centered regulatory network of EOS. Further, verification and diagnosis evaluation will be done in the follow-up sample in order to find the multiple molecular regulation networks serving as the biomarker of EOS diagnosis and treatment monitoring. The clarification of this subject may provide new thought on the study of schizophrenia biomarker, enrich the research contents of “Precision Medicine” of schizophrenia, and be a more effective strategy at the present level of diagnosis and treatment in schizophrenia.